Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Infusion of CD19-Specific Chimeric Antigen Receptor T-cells Produced by Rapid Personalized Manufacture for Patients With Advanced Lymphoid Malignancies

NCT04844086 is registered in ClinicalTrials.gov with Eden BioCell Ltd. as lead sponsor.

NCT NCT04844086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04844086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Infusion of CD19-Specific Chimeric Antigen Receptor T-cells Produced by Rapid Personalized Manufacture for Patients With Advanced Lymphoid Malignancies
Lead sponsor
Eden BioCell Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
March 2, 2021
Completion date
May 12, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, diffuse large b cell lymphoma, follicular lymphoma, high-grade b-cell lymphoma, mantle cell lymphoma, non-hodgkin's lymphoma refractory, non-hodgkin's lymphoma, relapsed, primary mediastinal large b cell lymphoma